397 Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Eloxx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.20 |
| 52 Week High | US$28.80 |
| 52 Week Low | US$3.20 |
| Beta | 2.06 |
| 11 Month Change | -17.66% |
| 3 Month Change | -76.37% |
| 1 Year Change | -87.62% |
| 33 Year Change | -98.57% |
| 5 Year Change | n/a |
| Change since IPO | -98.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 397 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3,420.7% | 1.2% | 1.3% |
| 1Y | -87.6% | -19.7% | 7.9% |
Return vs Industry: 397 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 397 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 397 volatility | |
|---|---|
| 397 Average Weekly Movement | 1,181.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 397's share price has been volatile over the past 3 months.
Volatility Over Time: 397's weekly volatility has increased from 581% to 1181% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 28 | Sumit Aggarwal | www.eloxxpharma.com |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology.
Eloxx Pharmaceuticals, Inc. Fundamentals Summary
| 397 fundamental statistics | |
|---|---|
| Market cap | €5.86m |
| Earnings (TTM) | -€39.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs 397 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 397 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$41.84m |
| Earnings | -US$41.84m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -19.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -494.1% |
How did 397 perform over the long term?
See historical performance and comparison